Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

The Effects of Obesity on the Comparative Effectiveness of Linezolid and Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Pneumonia

“…Additionally, our findings are consistent with previous research comparing linezolid and vancomycin in non-obese patients [15,[27][28][29][30]. Two meta-analyses which compared vancomycin and linezolid for nosocomial pneumonia, found no differences in clinical and microbiologic outcomes or mortality [29,30]. While many trials have demonstrated equivalent efficacy between linezolid and vancomycin [12,14], a recent prospective, randomized, doubleblind trial of MRSA pneumonia demonstrated higher clinical and microbiologic success rates with linezolid over vancomycin, however mortality was similar between the two groups [15].…”

“…This appears to be the only other study evaluating clinical outcomes among obese MRSA pneumonia patients treated with linezolid or vancomycin. Additionally, our findings are consistent with previous research comparing linezolid and vancomycin in non-obese patients [15,[27][28][29][30]. Two meta-analyses which compared vancomycin and linezolid for nosocomial pneumonia, found no differences in clinical and microbiologic outcomes or mortality [29,30].…”

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

“…In patients with CF infected with MRSA who are experiencing an acute pulmonary exacerbation, vancomycin and linezolid are the first-line antimicrobial choices (34,35). Dosing of vancomycin is based on the patient's weight and creatinine clearance.…”

A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection

“…Nephrotoxicity in vancomycin patients treated more than doubled from 9.4 to 19.6% when recommended trough levels of 15-20 ug/ml were reached, causing decreases in renal clearance from a 2008 study [8]. In a meta-analysis of eight randomized control trials of linezolid versus vancomycin for MRSA pneumonia, Walkey et al Additionally, the risk for adverse events was not different between the two antibiotic classes (p = 0.48) [9]. Conversely, in a recent prospective clinical trial, Wunderink et al documented clinical superiority of linezolid over vancomycin in the treatment of MRSA pneumonia infection, where vancomycin was dose-optimized and 58% of linezolid-treated patients achieved clinical success versus 47% of vancomycin-treated patients (p =.042), and nephrotoxicity occurred more frequently with vancomycin (18.2% vs linezolid, 8.4%) [10].…”